|
Advanced Oncotherapy PLC - London-based provider of proton therapy for cancer treatment - On Friday, says it is not in a position to publish its accounts for the year ended December 31, 2022, and the unaudited interim results for the six months ended June 30, together with the 2022 annual report. Explains the 2023 interim results are contingent on the finalisation and publication of the 2022 annual report. Shares in the company were suspended on June 30 pending clarification of its financial position. Company says it continues to work on its recapitalisation plan with a view to further funding being secured, including bridge financing which is required to alleviate its immediate financing needs. Discussions on the bridge financing are at an advanced stage but it has not entered into any agreements with investors nor have any funds been received from investors. Intends to provide a more detailed update on the prospective recapitalisation and funding plan in early October. Current stock price: suspended at 1.75 pence 12-month change: down more than 99% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
